BIOA
BioAge Labs, Inc
NASDAQ: BIOA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$18.19
-7.76% today
Updated 2026-06-05
Market cap
$713.02M
P/E ratio
—
P/S ratio
69.12x
EPS (TTM)
$-2.40
Dividend yield
—
52W range
$4 – $24
Volume
0.4M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
6.3
Growth
B8.5
Quality
A2.5
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
5.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$49.50
+172.13%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 5.79 — safe zone
+ Revenue growth 91.00% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-24.07M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $8.99M | $10.32M |
| Net income | $-39.72M | $-63.85M | $-71.11M | $-80.61M | $-22.25M |
| EPS | — | — | — | — | $-2.40 |
| Free cash flow | $-36.28M | $-37.53M | $-51.89M | $-82.35M | $-24.07M |
| Profit margin | — | — | — | -896.11% | — |
Peer comparison
Smart narrative
BioAge Labs, Inc trades at $18.19. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 5.79, it sits in the safe zone. TTM revenue stands at $10.32M.
Frequently asked questions
What is BioAge Labs, Inc's stock price?
BioAge Labs, Inc (BIOA) trades at $18.19, on a P/S of 69.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is BioAge Labs, Inc overvalued?
BioAge Labs, Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of BioAge Labs, Inc (BIOA)?
The 12-month analyst consensus target is $49.50, about 172.1% above the current $18.19. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is BioAge Labs, Inc's revenue?
BioAge Labs, Inc's trailing twelve-month revenue is $10.32M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
BioAge Labs, Inc's Altman Z-Score is 5.79, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio69.12x
ROE-23.72%
Beta—
50D MA$17.27
200D MA$13.22
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.4M
Performance
1 week+0.00%
1 month-11.10%
3 months-16.13%
YTD+18.67%
1 year—
3 years—
5 years—